About nurix therapeutics inc - NRIX
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company. It engages in the business of discovering, developing, and commercializing innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. The company was founded by John Kuriyan, Michael Rapé, and Arthur Weiss in 2009 and is headquartered in Brisbane, CA.
NRIX At a Glance
Nurix Therapeutics, Inc.
1600 Sierra Point Parkway
Brisbane, California 94158
| Phone | 1-415-660-5320 | Revenue | 83.98M | |
| Industry | Biotechnology | Net Income | -264,457,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 53.953% | |
| Fiscal Year-end | 11 / 2026 | Employees | 317 | |
| View SEC Filings |
NRIX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 18.246 |
| Price to Book Ratio | 3.341 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.729 |
| Enterprise Value to Sales | 11.849 |
| Total Debt to Enterprise Value | 0.056 |
NRIX Efficiency
| Revenue/Employee | 264,921.136 |
| Income Per Employee | -834,249.211 |
| Receivables Turnover | 55.987 |
| Total Asset Turnover | 0.122 |
NRIX Liquidity
| Current Ratio | 7.018 |
| Quick Ratio | 7.018 |
| Cash Ratio | 6.857 |
NRIX Profitability
| Gross Margin | 77.547 |
| Operating Margin | -340.16 |
| Pretax Margin | -314.00 |
| Net Margin | -314.905 |
| Return on Assets | -38.383 |
| Return on Equity | -49.629 |
| Return on Total Capital | -44.486 |
| Return on Invested Capital | -46.439 |
NRIX Capital Structure
| Total Debt to Total Equity | 10.344 |
| Total Debt to Total Capital | 9.375 |
| Total Debt to Total Assets | 7.932 |
| Long-Term Debt to Equity | 9.82 |
| Long-Term Debt to Total Capital | 8.90 |